Prolias Technologies
Prolias Technologies is an emerging molecular diagnostics company focusing on predictive and prognostic genetic cytology .
- Stage Full Product Ready
- Industry Biotechnology
- Location New York City, NY, USA
- Currency USD
- Founded January 2012
- Employees 4
- Website proliastechnologies.com
Company Summary
Our novel molecular tests provide a definitive pathological diagnosis that allows more accurate utility of surgical procedures and treatment decisions. Prolias Technologies has two products ready for commercialization: THYMIRA™ Panel (miRNA biomarker analysis to differentiate between malignant and benign thyroid nodules) and ARMIRA™ Panel (a non-invasive molecular diagnostic test to diagnose kidney rejection).
Team
-
Joe HernandezChairman and CEO
Mr. Hernandez obtained a Bachelor of Science degree in Neuroscience and graduate degrees in Molecular Genetics and Business Administration from The University of Florida. He has been published in several highly-respected scientific journals and presented at numerous scientific meetings. He has held senior level marketing, sales and business development positions at Digene Corporation, Affymetrix, Inc., and Merck. He founded and ran IBI, an MIT sp
-
George ElstonCFO
Mr. Elston is the Managing Partner of Chatham Street Partners, a life sciences transaction advisory firm and has raised over $100M in financing and business development transactions for biotechnology firms. Mr. Elston was most recently Chief Financial Officer of Optherion, Inc., a biopharmaceutical Company he successfully helped build and sell, and he was previously a senior executive at Elusys Therapeutics, Inc., a privately held biopharmaceutic
-
Justina GrossmanDirector of Sales and Marketing
Mrs. Grossman received an MBA in Pharmaceutical Management & Marketing from Drexel University and holds a Bachelor of Science degree from Villanova University. She is a dynamic sales and marketing professional with a proven track record of launching new brands and driving sales growth for leading diagnostic, biotechnology and pharmaceutical firms. She has held positions for both large and small healthcare companies including Mryiad Genetics, Lina
Advisors
-
Thompson HinesLawyerUnconfirmedPWCAccountantUnconfirmed
Previous Investors
-
Private AngelUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.